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Abstract
The interest in screening lysosomal storage disorders (LSDs) in newborns and high-risk 
population has increased in the last years due to the availability of novel treatment strategies 
coupled with the development of diagnostic techniques. We report the development of a short-
incubation mass spectrometry-based protocol that allows the detection of Gaucher, Niemann-Pick 
A/B, Pompe, Fabry and mucopolysaccharidosis type I disease within four hours including sample 
preparation from dried blood spots. Optimized sample handling without the need of time-
consuming offline preparations such as liquid-liquid and solid-phase extraction, allows the 
simultaneous quantification of five lysosomal enzyme activities using a cassette of substrates and 
deuterated internal standards. In a first clinical evaluation, we tested 825 unaffected newborns and 
16 patients with LSDs using a multiplexed, multidimensional UHPLC-tandem mass spectrometer. 
All affected patients were identified accurately and could be differentiated from non-affected 
newborns. In comparison to previously published two-day assays, which included an overnight 
incubation, this protocol enabled the detection of lysosomal enzyme activities from sample to first 
result within half a day. Due to high grade of automation and simplified sample preparation, this 
assay could be used for urgent clinical diagnostics needed for suspected patients admitted to a 
hospital, as well as for routine newborn and high-risk population screening.
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INTRODUCTION
Lysosomal storage disorders (LSDs) result in the accumulation of macromolecular 
substrates that would normally be degraded by enzymes involved in lysosomal metabolism. 
These diseases have a progressive course, and might occur at any age affecting a number of 
different tissues and organ systems.1 New impetus for the development of diagnostic 
techniques was acquired by the availability of novel treatment strategies including enzyme 
replacement, stem cell transplantation and substrate reduction.2 However, clinical 
diagnostics of LSDs is still a technological challenge, time-consuming, and additional 
personnel and equipment is needed. In addition to fluorescent methods using 4-
methylumbelliferone, efforts have been made to use tandem mass spectrometry (MS/MS) as 
the method of choice particularly for high-throughput analysis in routine newborn screening 
laboratories.3 In this context it is mandatory to achieve high laboratory standards in terms of 
technical proficiency and reproducibility of results; hence quality control materials provided 
by the Newborn Screening Quality Assurance Program at the Centers for Disease Control 
and Prevention (CDC, Atlanta, GA) are available.4
Protocols for analyzing lysosomal enzyme activities continuously evolved, and were refined 
and optimized, but the complexity of sample preparation prior to mass spectrometry 
including liquid-liquid extraction (LLE), solid phase extraction (SPE), and the handling of 
hazardous organic compounds such as ethyl acetate, still remains.5, 6 Novel aspects such as 
online multi-dimensional chromatography prior to flow injection analysis facilitate ease-of-
use sample introduction and increased speed of analysis.7, 8 Our research group previously 
reported the use of TurboFlow™ (short for Turbulent Flow Chromatography) for online 
sample clean-up to remove matrix interferences such as salts, proteins and detergents for the 
analysis of lysosomal enzyme activities in DBS.9 Subsequently, purified analytes of interest 
that were removed from potential matrix interferences were transferred from a TurboFlow 
column to an analytical column for ultra high performance liquid chromatography (UHPLC) 
separation prior to MS/MS analysis in order to separate enzymatic products from residual 
substrate. This simplified protocol has recently been evaluated in a comprehensive pilot 
screening of more than 8,500 newborns to demonstrate the technical feasibility and 
robustness.10
Nonetheless, for future implementation of high-throughput LSD assays in routine clinical 
diagnostics, sample handling and mass spectrometric analysis has to be simplified; 
specifically, sample pretreatment, speed of analysis and finally detection must become more 
integrated.11
The aim of this study was to develop a mass spectrometry based protocol to eliminate long 
incubation times of more than 16 to 20 hours (two-day protocols with an overnight 
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incubation), and to optimize and modify sample-handling prior to MS/MS analysis, to 
provide rapid and accurate detection of lysosomal enzyme activities within several hours.
EXPERIMENTAL SECTION
Materials and enzymatic assay
Substrates and internal standards were provided by the Newborn Screening Translation 
Research Initiative, Centers for Disease Control and Prevention, Atlanta, GA, USA. All 
other chemicals, HPLC-grade acetonitrile, isopropanol, acetone were purchased by Merck 
Chemicals; formic acid and trifluoroacetic acid from Sigma Aldrich Co. LLC, St. Louis, 
MO, USA; Cyclone-P™ (0.5×50mm) TurboFlow-columns and Hypersil Gold C8 (1.9µ, 
50×2.1mm) columns were purchased from Thermo Fisher Scientific Inc., MA, USA; and 
microplates 96/U, microplates 96/F and deep well plates by Eppendorf AG, Hamburg, 
Germany.
3.2-mm (1/8-inch) punches from DBS of 16 known patients with LSDs and 825 of non-
affected newborns were tested in parallel with a new short (three hours) incubation protocol 
and compared to a previously published method with an overnight incubation of 16 to 20 
hours.10 For the detection of all five lysosomal enzyme activities two punches from a DBS 
card in two separate 96well -plates were needed (Figure 1). Punch 1 was used for the 
detection of acid β–glucocerebrosidase (ABG; Gaucher disease), acid sphingomyelinase 
(ASM; Niemann-Pick A/B disease), α–glucosidase (GAA; Pompe disease) and α–
galactosidase; GLA; Fabry disease), respectively. Punch 2 was used for α–L–iduronidase 
(IDUA; mucopolysaccharidosis type I) analysis. The first punch was diluted with 60µl 
extraction buffer (20 mmol/L sodium phosphate; pH 7.1), and aliquots of 10µL were used to 
perform separate incubations for ABG, ASM, ABG, GAA and GLA in specific buffer 
systems containing a cassette of enzyme specific substrates and internal standards. The 
second punch was directly incubated with 30µl specific IDUA buffer. Incubation was 
performed at 37°C for three hours. The incubation was stopped by adding 100µL stopping 
solution (80% acetonitrile plus 0.2% formic acid). All aliquots were transferred in a new 
deep-well plate covered with aluminum foil and centrifuged at 3000g for 15 min prior to 
mass spectrometry analysis.
TurboFlow/UHPLC-MS/MS analysis
We used a previously described online-sample clean-up UHPLC method for sample 
analysis.9, 10 A Transcend™ TLX-2 UHPLC system with quaternary pumps was used 
(Thermo Fisher Scientific). The mobile phases were; A = 0.1% formic acid, 0.01% TFA in 
water, B = 0.1% formic acid, 0.01% TFA in acetonitrile, C = 45:45:10 isopropanol/
acetonitrile/acetone. The sample injection volume was 10 µL. The Transcend system 
employs two TurboFlow-HPLC channels, each with two six-port valves configured in 
focusing mode (recovered analytes from the TurboFlow column were transferred and 
focused on a subsequent UHPLC column for further separation).12 Samples were separated 
from matrix components during the loading step by TurboFlow chromatography using a 
Cyclone-P column with aqueous mobile phase. After buffer-salts, proteins and DBS 
residuals were rinsed away, the valves were switched and the extracted analytes were back-
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flushed off the TurboFlow column by the contents of a 200µl eluting loop filled with 20:80 
mobile phase A/mobile phase B and focused on a Hypersil Gold C8 UHPLC column. All 
analytes were separated using a linear gradient from 0% to 100% B in 40 seconds.10 The 
columns were then washed and re-equilibrated for the next injection. The system was 
operated by Aria™ Software V 1.6.3 (Thermo Fisher Scientific). The total run time for one 
TurboFlow/UHPLC experiment was 4 min per channel. MS/MS data acquisition started 2.15 
min after injection and continued for 90 seconds until all analyte signals were recorded. 
MS/MS analysis was performed on a TSQ Quantum Ultra™ (Thermo Fisher Scientific) 
equipped with an HESI-II heated electrospray probe and operated by Xcalibur™ V 
2.1.0.1139 (Thermo Fisher Scientific). We used selected-reaction monitoring (SRM) 
transitions for the five products and their respective internal standards. The amount of 
product was calculated from the ion abundance ratio of the product to internal standard for a 
sample multiplied by the amount of added internal standard, divided by the incubation time.
Statistical Analysis
All mass spectrometry data were analyzed with LCquan™ 2.6.0.1128 (Thermo Fisher 
Scientific). We used SPSS version 16·0 (SPSS Inc,, Chicago, Ill, USA) for data analysis.
RESULTS
Development of a short-incubation protocol
We have optimized the workflow for all pre-analytical steps in terms of sample preparation 
prior to mass spectrometry analysis. This included centrifugation, sample shaking and liquid 
handling steps (Figure 1). Using these optimizations, sample preparation time before and 
after incubation could be reduced to approximately 30 min each (for up to 90 samples plus 
quality control materials). Different incubation times of one, three, six and 20 hours were 
tested. Representative data for GAA are displayed in Figure 2, including different incubation 
times and their respective peak intensities of product versus product/internal-standard ratios. 
An incubation time of three hours was chosen and revealed coefficients of variation (CVs) 
of CDC quality control material below 11% (Table 3), and all affected patients could be 
differentiated from normal newborns (Table 1 and 2). Subsequently, the samples were 
injected into a multiplexed, multidimensional TurboFlow/UHPLC-MS/MS system. 
TurboFlow methodology enables the removal of salts, buffers, detergents, residual proteins, 
endogenous metabolites and significant amounts of un-reacted substrate prior to flow 
injection MS/MS analysis without the need for time-consuming offline sample preparation 
such as LLE and SPE. The total time for analysis was four minutes per sample, and with the 
use of staggered injections (dual-channel TLX-2 system with two TurboFlow and two 
analytical columns), the effective analysis time per sample was finally reduced to 2 min. In 
summary, pre-sample treatment (approximately one hour), short-incubation (three hours) 
and TurboFlow/UHPLC-MS/MS (two min per sample), provided the first results after four 
hours. Using this protocol, one 96-well plate with around 90 samples including quality 
controls could be analyzed within seven hours.
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Clinical evaluation
We analyzed a total of 16 patients with known LSDs (four patients with Pompe, five with 
Gaucher, five with Fabry, one with Niemann-Pick A/B, and one with MPS I disease) for 
clinical evaluation. We compared the short-incubation with our previous developed 
reference protocol (16-20 hours incubation).10 In Table 1, a detailed overview of all single 
enzyme activities using short versus the long incubation time is displayed, and we did not 
observe any statistical difference between both protocols in this first clinical setup. In 
addition, we analyzed all five lysosomal enzyme activities in 825 normal non-affected 
newborns (Table 2). All affected patients could be differentiated from normal newborns in 
this first pilot study by using the 0.5th percentile of normal newborns as a preliminary cut-
off value. Certainly, further studies with a larger number of newborns for cut-off 
determination are needed. For evaluation, we analyzed quality control materials provided by 
the CDC. Our results were compared successfully with those provided by the CDC with 
high coefficients of determination ranging from 0.974 to 0.998 (Table 3). The CVs were in 
the range from 3.3 to 11.0% (Table 3).
We concluded that this time saving protocol could be used for different clinical areas 
including selective metabolic screening for suspected patients at risk in a hospital, as well as 
for newborn or high-risk population screening.
DISCUSSION AND CONCLUSION
Currently, routine newborn screening for LSDs has been introduced for Pompe disease in 
Taiwan13 and for Krabbe disease in the State of New York.14 The Austrian Newborn 
Screening center15 and others, e.g. in Washington State6, have successfully started pilot 
studies using multiplexed MS/MS screening assays.16–18 The aim of this study was to 
develop a mass spectrometry based protocol for the rapid and accurate detection of 
lysosomal enzyme activities. Previously published protocols used 16-20 hours incubation 
time.3, 5, 10 We report the simplification and optimization of pre-analytical sample 
preparation to decrease the incubation time from 16–20 to three hours.
We used TurboFlow technology for sample clean-up prior to flow injection MS/MS 
analysis. The proof of concept using this technology was published recently by our research 
group.9 Moreover, in a first comprehensive clinical evaluation we could demonstrate that the 
technology is robust and accurate to detect patients with diminished lysosomal enzyme 
activity and to differentiate them from normal newborns.10 We took advantage of online 
sample clean-up using multidimensional chromatography that eliminates time-consuming 
and laborious protocol steps such as LLE and SPE, the use of organic compounds such as 
ethyl acetate3, 5, 19, and reduces the need for large amounts of consumables. Benefits of 
using TurboFlow columns were described in a large number of varied analytical 
environments, drug discovery and pharmacokinetics, metabolite profiling, and clinical 
applications.12, 20, 29 The combination of both a TurboFlow and an analytical columns, 
improved the multiplexed enzymatic assay by separating enzymatic products from residual 
substrates. This is of importance because previously published LSD assays reported the 
potential interference of the enzyme product signal from excess substrate due to in-source 
fragmentation.7 The higher resolving power of UHPLC, completely eliminates such 
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interferences while keeping total analysis time to two minutes per sample and facilitates the 
expansion of the screening panel.
However, one drawback of using MS/MS-based assays for LSDs was the long enzyme 
incubation time of more than 16 hours that required two-day protocols (with an overnight 
incubation). We optimized and adapted our previously published protocol and modified the 
work-flow (Figure 1). This allows the reduction of DBS incubation time with a cassette of 
substrates and deuterated internal standards from 16 to three hours. Sista and co-workers 
reported the use of a digital microfluidic platform to perform multiplexed enzymatic 
analysis using fluorescence with 4-methylumbelliferone within two hours on a small set of 
samples. However, it was restricted to two LSDs (Pompe and Fabry disease), and still 
needed evaluation.21 Conventional fluorescence methods usually include incubation times of 
more than three to 20 hours depending on the respective lysosomal enzyme and sensitivity 
of the assay.22
One limitation of the current protocol is the use of several buffer systems for different 
enzymes, and the requirement of a second DBS punch for IDUA due to low enzyme activity. 
In addition, the lysosomal enzyme activity for galactocerebrosidase (GALC; Krabbe 
disease) was also reported to be very low9, 23, and thus it was not possible to include this 
LSD in the current assay. However, novel buffer systems for the combined incubation of 
more than 6 or 9 enzymes simultaneously are on the horizon including substrates for 
mucopolysaccharidosis type II, IVA and VI 24–27, and were presented recently by Gelb and 
his research group.28 These new buffer systems might allow the incubation of several 
enzymes in one reaction vial, and might also be used for reducing the incubation time.
Our results using the short-incubation assay for Gaucher, Niemann-Pick A/B, Pompe, Fabry 
and mucopolysaccharidosis type I disease from DBS were in close agreement with 
previously published standard incubation time (16–20 hours) in our clinical reference 
laboratory. The mean activities for ABG, ASM, GAA, GLA and IDUA using short-
incubation protocol with 3 hour time were similar to those obtained using 16 to 20 hours 
incubation time. There was clear separation between normal non-affected newborn samples 
and confirmed affected samples for all five LSDs despite the much lower incubation time.
In conclusion, we successfully demonstrated and evaluated the performance of a 
multiplexed mass spectrometry-based assay to screen for Pompe, Fabry, Niemann-Pick A/B 
and Gaucher and mucopolysaccharidosis type I diseases using a short-incubation of three 
hours. This protocol can be used for selective metabolic screening for patients who are 
suspected to LSDs, and for newborn and high-risk population screening in both routine and 
research studies.
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Figure 1. 
Optimized workflow for the analyses of up to five lysosomal enzyme activities 
simultaneously from dried blood spots within four hours.
ABG, acid β–glucocerebrosidase; ASM, acid sphingomyelinase; GAA, α–glucosidase; 
GLA, α–galactosidase; IDUA, α–L–iduronidase.
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Figure 2. 
Exemplary data for GAA including different incubation times and their respective peak 
intensities of product versus product to internal standard ratios.
GAA, α–glucosidase; cps, counts per second; P, product; S, substrate
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